The most straightforward benefit is weight reduction
Both semaglutide and Tirzepatide are administered as subcutaneous injections, typically in the abdomen, thigh, or upper arm
In this article, well compare and contrast semaglutide and liraglutide to help you decide which medication best suits you
Worthington, PhD, and medically reviewed and edited by Tod Cooperman, MD, the founder of Consumer Lab (and who has agreed to do a chat with me, which we are in the process of scheduling)
These insights will help you make smart choices to support your cellular health and overall wellbeing in the years ahead
The response from many of those employers has been swift: Blue Cross Blue Shield of Massachusetts dropped GLP-1 coverage for obesity treatment for employers with fewer than 100 employees at the start of 2026 Harvard Pilgrim Health Care and Blue Cross Blue Shield of Michigan both dropped weight-loss GLP-1 coverage in 2026 HCA Healthcare one of the countrys largest hospital systems notified employees that its GLP-1 coverage was ending after usage surged 90% in a single year, directing workers instead toward manufacturer cash-pay programs Several other employers have stopped short of elimination but have tightened requirements dramatically restricting coverage only to patients with a formal diabetes diagnosis and removing access for patients using GLP-1s for weight management alone. Why Are Employers Cutting This Coverage Now